ILMN

As of 2026-10-26, ILMN scores 53out of 100 on QNTM’s five-factor quantitative model, a moderate conviction reading. The score blends momentum, quality, volume, value and sentiment, then adjusts for the current macro regime. ILMN trades at $271.04, 83% above the band ceiling.

ILMN scores 53 out of 100 on QNTM's five-factor model — a moderate reading — neither strongly favored nor flagged for weakness at 53. Its strongest factor is momentum at 78 (strong), where price trend and relative strength are working in its favor, followed by quality at 46. The weakest is sentiment at 36, where sentiment signals are working against it. Among Healthcare stocks it ranks in roughly the top 38% of the Healthcare names the model scores.

On valuation, ILMN is priced near the top of its recent range — the rich end on the model's valuation read. The blended composite before the macro overlay was 54. Same-sector names the model rates nearby include HALO, VEEV, THC.

This is a descriptive factor read on ILMN, recomputed each trading day and shown with its reasoning — not a recommendation to buy, hold or sell. The score reflects where ILMN sits on the model's measures today, and can change as new data arrives.

FACTOR BREAKDOWN

VALUATION RANGE

QNTM’s descriptive fair-value band for ILMN runs $91.89–$148.38. Current price $271.04 sits 83% above the band ceiling. This is valuation context, not a price target.

OTHER HEALTHCARE NAMES

QNTM provides quantitative model outputs for informational and educational purposes only. It is not investment advice and QNTM is not a registered investment adviser. Scores are rankings, not buy/sell recommendations. Data as of 2026-10-26.